Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft

Leukemia volume 18, pages 354–355 (2004)Cite this article

TO THE EDITOR

Idiopathic hypereosinophilic syndrome (HES) is characterized by chronic hypereosinophilia with organic dysfunction.1,2 In a recently published report, Cools et al3 described response in nine of 11 HES patients treated with imatinib. In five of these nine patients, fusion of the Fip1-like1 (FIP1L1) gene to the PDGFR alpha (PDGFRA) gene was detected, leading to expression of an activated tyrosine kinase that is thought to be a target of imatinib. We report here a case of a leukemic form of HES refractory to intensive treatment (including allograft) in whom sustained clinical and molecular response was induced by imatinib.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Brito-Babapulle F . The eosinophilias, including the idiopathic hypereosinophilic Syndrome. Br J Haematol 2003; 121: 203–223.

    Article  Google Scholar 

  2. Vardiman JW, Harris NL, Brunning RD, The World Health Organization (WHO). Classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.

    Article  CAS  Google Scholar 

  3. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of Imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201–1214.

    Article  CAS  Google Scholar 

  4. Ueno NT, Anagnostopoulos A, Rondon G, Champlin RE, Mikhailova N, Pankratova OS et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002; 119: 131–134.

    Article  Google Scholar 

  5. Chockalingam A, Jalil A, Shadduck RK, Lister J . Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction. Bone Marrow Transplant 1999; 23: 1093–1094.

    Article  CAS  Google Scholar 

  6. Gabert J, Beillard E, van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase qchain reaction (RQ-PCR) of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer Program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'Onco-Hématologie, Hôpital St Vincent, Groupe Hospitalier de l'Institut Catholique, Lille, 59000, France

    C Rose, S Dupire, E Bourgeois & N Cambier

  2. Service d'Hématologie A Hôpital Calmette and Inserm U524 CHRU, Lille, 59000, France

    C Roche-Lestienne, N Grardel & C Preudhomme

Authors
  1. C Rose
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Dupire
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Roche-Lestienne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N Grardel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Bourgeois
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Cambier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Preudhomme
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C Preudhomme.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rose, C., Dupire, S., Roche-Lestienne, C. et al. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia 18, 354–355 (2004). https://doi.org/10.1038/sj.leu.2403229

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403229

This article is cited by

Search

Advanced search

Quick links